The Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID) was established by the Department of Medicine to support both fundamental and translational research on human disease.
It houses up to 250 scientists working within 25 research groups. Our work focusses on understanding the pathogenesis and improving the management of immune-related disorders and transforming our understanding of how the infectious agents interact with humans.
CITIID transforms immunity and infection research in Cambridge by providing researchers with advanced facilities that are in close proximity and enable them to optimise their work on human immune, inflammatory and infectious diseases. By bringing together its clinical capabilities and key industry partners, CITIID is also well-placed to drive therapeutic breakthroughs, improve patient outcomes and advance population health both in the UK and abroad.
- Identification of pathway that enables resistance to tuberculosis – Ramakrishnan Group 29 Sept 2022
- Modis Group – Science Advances - Executive summary The Modis Group has found an endogenous retrovirus in hookworm with an envelope protein with a fold remarkably…
- Modis Lab – A mutation in MDA5 associated with inherited autoinflammatory disease prevents structural discrimination between viral and cellular RNA - A mutation in MDA5 associated with inherited autoinflammatory disease prevents structural discrimination between viral and cellular RNA MDA5 is one…
- The microbiologist tackling humanity’s next biggest killer -
- Spread of Delta SARS-CoV-2 variant driven by combination of immune escape and increased infectivity -
- Upgrading PPE for staff working on COVID-19 wards cut hospital-acquired infections dramatically -
- Key mutations in Alpha variant enable SARS-CoV-2 to overcome evolutionary weak points -
- Ravi Gupta elected to the Academy of Medical Sciences -
- Single-cell transcriptomics and proteomics profiling of COVID19 samples reveals immune and HSPC changes that are differentially associated with disease severity -
- Infographics and risk factors associated with seroprevalence of SARS-CoV-2 antibodies in HCWs - As a component of our COVID research we conducted a seroepidemiology study to measure exposure to SARS-CoV-2 at Addenbrookes hospital.…
- Genomics study identifies routes of transmission of coronavirus in care homes -